Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
PRNewswire (Tue, 9-Dec 8:29 AM ET)
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
Globe Newswire (Mon, 1-Dec 7:00 AM ET)
PRNewswire (Wed, 19-Nov 6:18 PM ET)
PRNewswire (Wed, 19-Nov 2:10 PM ET)
Halper Sadeh LLC Encourages CMA, ADVM, HOUS Shareholders to Contact the Firm to Discuss Their Rights
Globe Newswire (Tue, 18-Nov 7:15 PM ET)
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
PRNewswire (Mon, 27-Oct 1:01 PM ET)
Business Wire (Mon, 27-Oct 9:40 AM ET)
Business Wire (Sat, 25-Oct 11:41 AM ET)
Globe Newswire (Fri, 24-Oct 2:57 PM ET)
PRNewswire (Fri, 24-Oct 1:47 PM ET)
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Adverum Biotechnologies trades on the NASDAQ stock market under the symbol ADVM.
As of January 12, 2026, ADVM stock price was flat at $4.36 with million shares trading.
ADVM has a beta of 0.77, meaning it tends to be less sensitive to market movements. ADVM has a correlation of 0.03 to the broad based SPY ETF.
ADVM has a market cap of $96.26 million. This is considered a Micro Cap stock.
Last quarter Adverum Biotechnologies reported $0 in Revenue and -$2.03 earnings per share. This fell short of revenue expectation by $-8 million and missed earnings estimates by -$1.48.
In the last 3 years, ADVM traded as high as $29.70 and as low as $1.78.
The top ETF exchange traded funds that ADVM belongs to (by Net Assets): VTI, VXF, MSSM.
ADVM has underperformed the market in the last year with a price return of -3.5% while the SPY ETF gained +19.2%. ADVM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.0% and 0.0%, respectively, while the SPY returned +3.9% and +0.7%, respectively.
ADVM support price is $4.36 and resistance is $4.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADVM shares will trade within this expected range on the day.
